Correction to: Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era

Patricia K Coyle¹, Anne Gocke², Megan Vignos^{3

4}, Scott D Newsome⁵

Affiliations

¹ Department of Neurology, Stony Brook University Medical Center, Stony Brook, NY, USA.
² Biogen, Cambridge, MA, USA.
³ Biogen, Cambridge, MA, USA. megan.vignos@biogen.com.
⁴ US Medical MS Franchise and Interferons, Biogen, 133 Boston Post Rd, Weston, MA, 20493, USA. megan.vignos@biogen.com.
⁵ Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Published Erratum

Patricia K Coyle et al. Adv Ther. 2022 Jan.

. 2022 Jan;39(1):822-830.

doi: 10.1007/s12325-021-01967-5.

Patricia K Coyle¹, Anne Gocke², Megan Vignos^{3

4}, Scott D Newsome⁵

¹ Department of Neurology, Stony Brook University Medical Center, Stony Brook, NY, USA.
² Biogen, Cambridge, MA, USA.
³ Biogen, Cambridge, MA, USA. megan.vignos@biogen.com.
⁴ US Medical MS Franchise and Interferons, Biogen, 133 Boston Post Rd, Weston, MA, 20493, USA. megan.vignos@biogen.com.
⁵ Johns Hopkins University School of Medicine, Baltimore, MD, USA.

No abstract available

Erratum for

Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.
Coyle PK, Gocke A, Vignos M, Newsome SD. Coyle PK, et al. Adv Ther. 2021 Jul;38(7):3550-3588. doi: 10.1007/s12325-021-01761-3. Epub 2021 Jun 1. Adv Ther. 2021. PMID: 34075554 Free PMC article. Review.